ITCI News and Press, Intra-Cellular Therapies Inc. From 04/16/24

2024-04-16 09:01:36 ET More on Intra-Cellular Therapies Intra-Cellular Therapies Is On Fire Intra-Cellular Therapies, Inc. (ITCI) Q4 2023 Earnings Call Transcript Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy' I...

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery- Åsberg Depression Rating Scale (MADRS) to...

2024-04-02 17:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-02 15:38:04 ET More on Intra-Cellular Therapies Intra-Cellular Therapies Is On Fire Intra-Cellular Therapies, Inc. (ITCI) Q4 2023 Earnings Call Transcript Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy' I...

2024-03-23 15:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-19 08:43:59 ET More on Intra-Cellular Therapies Intra-Cellular Therapies Is On Fire Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy' Intra-Cellular Therapies Q4 2023 Earnings Preview Seeking Alpha’s...

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the promotion of Michael Halstead, J.D. to the posit...

2024-03-11 19:11:51 ET Summary Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand CAPLYTA's use to treat Major Depressive Disorder. CAPLYTA's growing acceptan...

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor ...

2024-03-03 00:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...